Pharmaceutical Technology1h
FDA grants ODD to Tempest’s hepatocellular carcinoma treatment
The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with hepatocellular carcinoma (HCC).
Pharmaceutical Technology1h
COVID-19: The global clinical trial landscape in 2024
The landscape of pandemic response has been transformed, with new standards being set for clinical excellence. A new report looks at emerging therapies, trial insights, and the innovations shaping the ...
Pharmaceutical Technology19h
Danish biotech Orbis secures $94m to develop oral versions of biologics
Orbis Medicines has raised €90m ($94m) in Series A funding to advance the development of its next-generation orally dosable macrocycle drugs.
Pharmaceutical Technology21h
FDA grants ODD to NMD Pharma’s Charcot-Marie-Tooth disease therapy
The US FDA has granted ODD to NMD Pharma’s oral lead development programme, NMD670, designed to treat Charcot-Marie-Tooth disease (CMT).
Pharmaceutical Technology22h
Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder
The decision follows a positive recommendation received from the Committee for Medicinal Products for Human Use (CHMP) in November 2024.
Pharmaceutical Technology23h
Amgen’s Imdylltra wins conditional MHRA licence for lung cancer
Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.
Pharmaceutical Technology23h
Heart failure market estimated to grow, driven by pipeline agents aimed at unmet needs
The heart failure market is expected to grow at a 9.6% CAGR from $13.5bn in 2022 to $33.7bn in 2032 in the 7MM.